Leap Therapeutics (LPTX) to Release Quarterly Earnings on Monday

Leap Therapeutics (NASDAQ:LPTX) is expected to release its earnings data before the market opens on Monday, March 17th. Analysts expect Leap Therapeutics to post earnings of ($0.39) per share for the quarter.

Leap Therapeutics Stock Down 0.2 %

LPTX opened at $0.44 on Monday. The business has a 50 day moving average price of $1.50 and a two-hundred day moving average price of $2.42. Leap Therapeutics has a 52 week low of $0.40 and a 52 week high of $4.79. The company has a market cap of $16.83 million, a PE ratio of -0.23 and a beta of 0.35.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Robert W. Baird lowered Leap Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $9.00 to $1.25 in a research note on Wednesday, January 29th. Baird R W lowered Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 29th. Finally, HC Wainwright lowered Leap Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 29th.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.